SCYNEXIS Inc. Announces BARDA Contract for SCY-247, Up to $214M

What Happened
SCYNEXIS Inc. announced on its Form 8-K (filed Sept. 28, 2026) that it entered into an Award/Contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) on Sept. 25, 2026 to support development of its second‑generation antifungal candidate SCY‑247. The contract provides for up to $214 million in potential non‑dilutive funding, with an initial base period beginning Sept. 2026 that provides approximately $18.5 million to advance oral and IV SCY‑247 into a Phase 2 study for invasive candidiasis.

Key Details

• Contract counterparty: BARDA (within ASPR, HHS); contract number 75A50126C00007.
• Potential total funding: up to $214 million (non‑dilutive).
• Initial base period funding: ~ $18.5 million to support Phase 2 initiation (commencing Sept. 2026).
• Options: BARDA may exercise up to six options over as long as ten years to potentially fund development through NDA submissions for two indications (treatment of invasive candidiasis and prevention of invasive fungal infections in high‑risk patients).
• Structure: cost‑share arrangement (BARDA supports eligible direct and G&A costs); SCYNEXIS expects to fund its near‑term share within its existing operating plan.
• Corporate impact: SCYNEXIS says its development plans for lead candidate SCY‑770 (for ADPKD) and projected cash runway into 2029 remain unchanged.
• Disclosure: the company issued a press release (filed as Exhibit 99.1) and plans to file the BARDA Contract as an exhibit to its 10‑Q (with confidential terms redacted).

Why It Matters
This BARDA award is material because it supplies substantial non‑dilutive funding specifically for SCY‑247, reducing the near‑term financing burden on shareholders and supporting progression to a Phase 2 study. The multi‑option, multi‑year structure could fund late‑stage development through NDA filings for two indications if fully exercised, representing a significant de‑risking of development cost—but future option exercise is at BARDA’s discretion. The company’s statement that SCY‑770 plans and cash runway into 2029 are unchanged is important for investors monitoring overall development timelines and funding needs.